Perkins Capital Management Inc holds a focused book of 79 reported positions worth $133.0M as of Q2 2026 (disclosed Jul 24, 2026, a ~24-day 13F lag). This quarter Vida Global Inc CL-A first appears in 13F filings, a listing rather than a purchase; they opened Creative Realities Inc and trimmed Natera Inc. Their largest long position is Natera Inc at 8% of the reported non-option book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
+1 sector below the cut, under 0.5% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Perkins Capital Management Inc
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Independent Investors Inc | 8 / 79 | $349.5M |
| Bedel Financial Consulting, Inc. | 16 / 79 | $443.0M |
| Fiduciary Family Office, LLC | 11 / 79 | $160.4M |
| Stembrook Asset Management, LLC | 8 / 79 | $44.1M |
| bLong Financial, LLC | 14 / 79 | $57.1M |
| Goelzer Investment Management, Inc. | 17 / 79 | $806.1M |
| Armstrong Henry H Associates Inc | 10 / 79 | $352.2M |
| Weatherly Asset Management L. P. | 15 / 79 | $479.1M |
Ranked by the share of each fund's own book sitting in the names it shares with Perkins Capital Management Inc: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Natera Inc COM | $11.0M | 40.6K | 8.3% | ▼−8.3% Reduced · −4K sh | |
| 2 | Eli Lilly & Co COM | $10.4M | 8.7K | 7.8% | ▼−1.7% Reduced · −150 sh | |
| 3 | Advanced Micro Devices Inc Del COM | $8.1M | 13.9K | 6.1% | ▼−10% Reduced · −2K sh | |
| 4 | Butterfly Network Inc COM | $7.3M | 867.6K | 5.5% | ▼−6.8% Reduced · −63K sh | |
| 5 | Axogen Inc COM | $6.8M | 147.8K | 5.1% | ▼−12% Reduced · −21K sh | |
| 6 | Inuvo Inc COM | $6.5M | 515.0K | 4.9% | ▼−12% Reduced · −67K sh | |
| 7 | Quicklogic Corp COM NEW | $5.1M | 257.6K | 3.9% | ▼−16% Reduced · −49K sh | |
| 8 | Idexx Labs Inc COM | $5.1M | 9.7K | 3.8% | —Held | |
| 9 | Backblaze Inc COM CL A | $4.9M | 308.7K | 3.7% | ▼−8.9% Reduced · −30K sh | |
| 10 | Microsoft Corp COM | $4.2M | 11.2K | 3.1% | ▼−2.1% Reduced · −242 sh | |
| 11 | Veracyte Inc COM | $3.5M | 60.0K | 2.6% | ▼−20% Reduced · −15K sh | |
| 12 | Ooma Inc COM | $3.4M | 177.0K | 2.6% | ▼−2.4% Reduced · −4K sh | |
| 13 | Personalis Inc COM | $3.2M | 239.0K | 2.4% | —Held | |
| 14 | Cryoport Inc COM PAR $0.001 | $3.1M | 199.9K | 2.4% | ▼−1.6% Reduced · −3K sh | |
| 15 | Ciena Corp COM NEW | $3.1M | 6.3K | 2.3% | —Held | |
| 16 | Lemaitre Vascular Inc COM | $2.4M | 25.3K | 1.8% | ▼−1.9% Reduced · −480 sh | |
| 17 | Magnite Inc COM | $1.9M | 98.6K | 1.4% | ▼−17% Reduced · −21K sh | |
| 18 | Abbott Laboratories COM | $1.8M | 20.3K | 1.4% | ▼−1.9% Reduced · −402 sh | |
| 19 | Usio Inc COM | $1.7M | 700.4K | 1.3% | ▼−0.2% Reduced · −2K sh | |
| 20 | Ondas Holdings COM NEW | $1.7M | 201.5K | 1.2% | ▼−0.2% Reduced · −500 sh | |
| 21 | Neogenomics Inc COM NEW | $1.6M | 110.0K | 1.2% | ▼−17% Reduced · −22K sh | |
| 22 | Perion Network Ltd SHS NEW | $1.6M | 165.2K | 1.2% | ▲+5.3% Added · +8K sh | |
| 23 | Neogen Corp COM | $1.6M | 177.5K | 1.2% | ▼−0.3% Reduced · −500 sh | |
| 24 | Crexendo Inc COM | $1.6M | 212.8K | 1.2% | ▲+9.2% Added · +18K sh | |
| 25 | Alphatec Hldgs Inc COM NEW | $1.5M | 175.2K | 1.1% | ▲+1.9% Added · +3K sh | |
| 26 | Abbvie Inc COM | $1.3M | 5.3K | 1.0% | ▼−0.7% Reduced · −35 sh | |
| 27 | Creative Realities Inc COM | $1.2M | 300.1K | 0.9% | ▲New New position | |
| 28 | Lucid Diagnostics Inc COM | $1.2M | 1.13M | 0.9% | ▼−0.1% Reduced · −1K sh | |
| 29 | Codexis Inc COM | $1.2M | 526.1K | 0.9% | ▼−0.3% Reduced · −1K sh | |
| 30 | Zeta Global Holdings Corp CL A | $1.1M | 55.9K | 0.8% | —Held | |
| 31 | Trisalus Life Sciences Inc COM | $1.1M | 235.1K | 0.8% | ▲+2.2% Added · +5K sh | |
| 32 | Tela Bio Inc COM | $1.0M | 1.38M | 0.8% | ▼−3.0% Reduced · −43K sh | |
| 33 | Biodesix Inc COM | $1.0M | 44.6K | 0.8% | ▼−0.4% Reduced · −165 sh | |
| 34 | Safe Pro Group Inc COM | $998K | 230.5K | 0.8% | ▼−0.3% Reduced · −750 sh | |
| 35 | Merck & Co Inc COM | $964K | 7.5K | 0.7% | ▼−3.2% Reduced · −250 sh | |
| 36 | Gilead Sciences Inc COM | $912K | 7.2K | 0.7% | —Held | |
| 37 | Viatris Inc COM | $855K | 53.8K | 0.6% | ▼−1.9% Reduced · −1K sh | |
| 38 | Pfizer Inc COM | $813K | 33.8K | 0.6% | ▼−6.0% Reduced · −2K sh | |
| 39 | Blacksky Technology Inc CL A NEW | $803K | 28.8K | 0.6% | —Held | |
| 40 | Apple Inc COM | $767K | 2.6K | 0.6% | —Held | |
| 41 | Profound Med Corp COM NEW | $760K | 114.3K | 0.6% | —Held | |
| 42 | US Bancorp COM NEW | $746K | 12.3K | 0.6% | ▼−1.6% Reduced · −200 sh | |
| 43 | Neuroone Med Technologies Co COM | $744K | 244.7K | 0.6% | ▲New New position | |
| 44 | Vida Global Inc COM | $700K | 250.0K | 0.5% | →Listed Newly reportable | |
| 45 | Target Corp COM | $620K | 4.8K | 0.5% | ▼−3.1% Reduced · −150 sh | |
| 46 | Owlet Inc CL A NEW | $611K | 106.5K | 0.5% | ▲+0.4% Added · +400 sh | |
| 47 | Elauwit Connection Inc COM | $598K | 55.5K | 0.4% | —Held | |
| 48 | Mdxhealth Sa SHS NEW | $580K | 1.41M | 0.4% | ▼−4.4% Reduced · −65K sh | |
| 49 | Seagate Technology Hldgs PL ORD SHS | $507K | 525 | 0.4% | ▼−4.5% Reduced · −25 sh | |
| 50 | Atricure Inc COM | $490K | 17.5K | 0.4% | ▼−33% Reduced · −9K sh |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/884300/holdings"
Use Arkolith to show PERKINS CAPITAL MANAGEMENT INC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Jul 24, 2026 | 24d | 79 | $133.0M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | Apr 23, 2026 | 23d | 86 | $106.7M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 4, 2026 | 35d | 91 | $125.9M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Oct 31, 2025 | 31d | 83 | $113.5M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 7, 2025 | 38d | 83 | $99.5M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 7, 2025 | 37d | 82 | $94.8M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 11, 2025 | 42d | 81 | $112.7M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Oct 31, 2024 | 31d | 84 | $106.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.